News & Press Releases

CELLERANT THERAPEUTICS, INC. ANNOUNCES FDA GRANTS REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR ROMYELOCEL-L TO PREVENT INFECTIONS DURING NEUTROPENIA
July 2, 2018


CELLERANT THERAPEUTICS, INC. PRESENTS PHASE 2 RESULTS SHOWING CLT-008 SIGNIFICANTLY REDUCES RISK OF INFECTIONS IN AML PATIENTS UNDERGOING STANDARD INDUCTION CHEMOTHERAPY
June 18, 2018


CELLERANT THERAPEUTICS, INC. CLT-008 PHASE 2 RESULTS SHOW SIGNIFICANT REDUCTION IN INFECTIONS AND DAYS IN HOSPITAL IN SEVERELY NEUTROPENIC AML PATIENTS
June 4, 2018


CELLERANT THERAPEUTICS, INC. TO PRESENT RESULTS OF PHASE 2 CLINICAL TRIAL OF CLT-008 AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2018 ANNUAL MEETING AND EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 23RD CONGRESS
May 17, 2018


Pinkal Desai | EHA 2018 | CLT008 reduces serious infections, antibiotic use and days of hospitalization during AML induction
May 17, 2018


 

Copyright ©2006-2018 Cellerant Therapeutics, Inc.